Epinefrine Medicine 04 June 2026 Extended indication Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over with a body weight of 15 kg or more. Therapeutic value Total cost € 3,500,000.00 Registration phase Registered Product Active substance Epinefrine Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Other chronic immune diseases Extended indication Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over with a body weight of 15 kg or more. Current proprietary name Already available biosimilars / generics Proprietary name EURneffy Manufacturer Alk Abello Portfolio holder Alk Abello Mechanism of action Receptor agonist Route of administration Nasal Therapeutical formulation Nose spray Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Alfa- en beta-adrenergische receptoragonist. Dit betreft de pediatrische indicatieuitbreiding naar patiënten van vier jaar met een lichaamsgewicht van 15kg of meer. EURneffy is al geregistreerd voor kinderen met een lichaamsgewicht van 30kg of meer. Registration Registration route Type of trajectory Particularity ATMP No Submission date 2025 Expected Registration March 2026 Orphan drug No Registration phase Registered Reimbursement Reimbursement request pending Medicine sluice Additional remarks Positieve CHMP-opinie in januari 2026, EC registratie in maart 2026. Zorginstituut Nederland beoordeelt of adrenaline neusspray (EURneffy®) vergoed kan worden. In juni of juli 2026 wordt het advies verwacht. Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume < 5,000 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Declaratiedata Additional remarks Er zijn zeer grof geschat 10.000 gebruikers van adrenaline tussen de vijf en veertien jaar oud. Kinderen met een lichaamsgewicht van 30kg zijn doorgaans tussen de acht en tien jaar oud. Het aantal kinderen dat adrenaline gebruikt met een lichaamsgewicht tussen de 15 en 30kg ligt waarschijnlijk in de duizenden. Expected cost per patient per year Cost € < 700.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Drugs.com (1) Additional remarks De prijs in de Verenigde Staten voor twee neussprays is $757.13 (ongeveer €696) (1). Potential total cost per year Total cost € 3,500,000.00 Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks